KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Change in Receivables (2017 - 2025)

BeOne Medicines (ONC) has disclosed Change in Receivables for 9 consecutive years, with -$2.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables fell 101.86% to -$2.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $165.0 million, a 49.93% decrease, with the full-year FY2025 number at $165.0 million, down 49.93% from a year prior.
  • Change in Receivables was -$2.3 million for Q4 2025 at BeOne Medicines, down from $93.9 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $353.8 million in Q4 2021 to a low of -$292.6 million in Q1 2022.
  • A 5-year average of $40.1 million and a median of $30.9 million in 2024 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: skyrocketed 263963.43% in 2021, then crashed 1336.7% in 2022.
  • BeOne Medicines' Change in Receivables stood at $353.8 million in 2021, then crashed by 105.48% to -$19.4 million in 2022, then skyrocketed by 330.96% to $44.8 million in 2023, then skyrocketed by 180.61% to $125.7 million in 2024, then tumbled by 101.86% to -$2.3 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Change in Receivables are -$2.3 million (Q4 2025), $93.9 million (Q3 2025), and $41.5 million (Q2 2025).